Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

被引：0
|
作者：
Backes, Floor [1 ]
Wei, Lai [1 ]
Copeland, Larry [1 ]
Cohn, David [1 ]
Fowler, Jeffrey [1 ]
Bixel, Kristin [1 ]
Cosgrove, Casey [1 ]
Hays, John [1 ]
Myers, Molly [1 ]
Dodd, Kelly [1 ]
O'Malley, David [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
120
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [21] A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Nagao, Shoji
    Kogiku, Ai
    Suzuki, Kazuhiro
    Shibutani, Takashi
    Yamamoto, Kasumi
    Jimi, Tomoatsu
    Kitai, Miho
    Shiozaki, Takaya
    Matsuoka, Kazuko
    Yamaguchi, Satoshi
    JOURNAL OF OVARIAN RESEARCH, 2020, 13 (01)
  • [22] Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Slomovitz, B. M.
    Coleman, R. L.
    Levenback, C.
    Jung, M.
    Gershenson, D. M.
    Wolf, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 278S - 278S
  • [23] A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Shoji Nagao
    Ai Kogiku
    Kazuhiro Suzuki
    Takashi Shibutani
    Kasumi Yamamoto
    Tomoatsu Jimi
    Miho Kitai
    Takaya Shiozaki
    Kazuko Matsuoka
    Satoshi Yamaguchi
    Journal of Ovarian Research, 13
  • [24] Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
    Moore, K. N.
    Oza, A. M.
    Colombo, N.
    Oaknin, A.
    Scambia, G.
    Lorusso, D.
    Konecny, G. E.
    Banerjee, S.
    Murphy, C. G.
    Tanyi, J. L.
    Hirte, H.
    Konner, J. A.
    Lim, P. C.
    Prasad-Hayes, M.
    Monk, B. J.
    Pautier, P.
    Wang, J.
    Berkenblit, A.
    Vergote, I
    Birrer, M. J.
    ANNALS OF ONCOLOGY, 2021, 32 (06) : 757 - 765
  • [25] FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer
    Moore, K. N.
    Vergote, I.
    Oaknin, A.
    Colombo, N.
    Banerjee, S.
    Oza, A. M.
    Pautier, P.
    Kelly, C. M.
    Malek, K.
    Birrer, M. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Chelariu-Raicu, Anca
    Levenback, Charles F.
    Slomovitz, Brian M.
    Bodurka, Diane C.
    Gershenson, David Marc
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Evaluating the duration of response with mirvetuximab soravtansine for treating platinum-resistant ovarian cancer Reply
    Matulonis, Ursula A.
    Lorusso, Domenica
    Oaknin, Ana
    Pignata, Sandro
    Dean, Andrew
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason A.
    Marin, Margarita Romeo
    Harter, Philipp
    Murphy, Conleth G.
    Wang, Jiuzhou
    Noble, Elizabeth
    Esteves, Brooke
    Method, Michael
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (29) : 4705 - 4706
  • [28] Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study
    Tatsuki, Shunsuke
    Shoji, Tadahiro
    Abe, Marina
    Tomabechi, Hidetoshi
    Takatori, Eriko
    Kaido, Yoshitaka
    Nagasawa, Takayuki
    Kagabu, Masahiro
    Aida, Takeshi
    Baba, Tsukasa
    ANTICANCER RESEARCH, 2022, 42 (09) : 4603 - 4610
  • [29] Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
    Matulonis, Ursula A.
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason A.
    Romeo, Marga
    Harter, Philipp
    Murphy, Conleth G.
    Wang, Jiuzhou
    Method, Michael W.
    Esteves, Brooke
    Coleman, Robert L.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Makhija, Sharmila
    Amler, Lukas C.
    Glenn, Dana
    Ueland, Frederick R.
    Gold, Michael A.
    Dizon, Don S.
    Paton, Virginia
    Lin, Chin-Yu
    Januario, Thomas
    Ng, Kimmie
    Strauss, Andreas
    Kelsey, Stephen
    Sliwkowski, Mark X.
    Matulonis, Ursula
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1215 - 1223
12345